Zura Bio

Zura Bio R&D per Employee

The R&D Spending per Employee of Zura Bio (ZURA) as of Nov 3, 2026 is 1.05 M USD. In the previous year, R&D Spending per Employee was 610,025.00 USD — a change of 72.46% (higher).

R&D per Employee

1.05 MUSD

YoY

72.46%

Last updated:

R&D Spending per Employee of Zura Bio is 2025 1.05 M USD. R&D Spending per Employee of Zura Bio was 2024 610,025.00 USD. It decreases by 72.46% higher compared to the previous year.

The Zura Bio R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2022
592,225.00 USD
Jan 1, 2023
1.10 M USD
Jan 1, 2024
610,025.00 USD
Jan 1, 2025
1.05 M USD
The Zura Bio R&D per Employee history
YEARR&D per EmployeeYoY
1.05 MUSD+72.46%
610,025.00USD-44.54%
1.10 MUSD+85.74%
592,225.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zura Bio Stock analysis

What does Zura Bio do? Zura Bio Ltd. develops novel medicines for immune disorders, focusing on clinical-stage therapeutics such as ZB-168 and torudokimab. ZB-168, an anti-IL7Rα inhibitor, targets diseases linked to IL7 and TSLP pathways, building on Phase Ib data in type 1 diabetes. Torudokimab, a monoclonal antibody neutralizing IL33, is in phase II development. The company monetizes through advancing these assets into later-stage clinical programs, leveraging their therapeutic potential for immune-related conditions. Zura Bio Ltd. generates revenue by progressing its pipeline candidates toward regulatory approval and commercialization. The firm's portfolio includes ZB-168 for immune disorders with a demonstrated safety profile in type 1 diabetes, and torudokimab targeting IL33-related conditions. These assets are developed for specific therapeutic indications, with ZB-168 expanding into new immune disorder applications based on existing clinical data. The company's primary revenue stream comes from the advancement of its clinical-stage assets, including ZB-168 and torudokimab, into phase II development. ZB-168 is positioned for diseases involving IL7 and TSLP pathways, while torudokimab addresses IL33-related conditions. Both products are developed for immune disorder treatments, with ZB-168 leveraging Phase Ib data in type 1 diabetes to support further development. Zura Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zura Bio stock

R&D Spending per Employee of Zura Bio is 1.05 M USD in 2025.

R&D Spending per Employee of Zura Bio changed from 610,025.00 USD to 1.05 M USD, representing a 72.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Zura Bio since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Zura Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Workforce — Zura Bio

EmployeesRevenue per EmployeeProfit per EmployeeMarket Cap per EmployeeEBIT per EmployeeEBITDA per EmployeeR&D per EmployeePP&E per Employee

All Key Metrics — Zura Bio